{"id":"NCT02422186","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","officialTitle":"A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-20","primaryCompletion":"2017-08-10","completion":"2017-08-10","firstPosted":"2015-04-21","resultsPosted":"2019-04-24","lastUpdate":"2025-04-29"},"enrollment":139,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Treatment-Resistant"],"interventions":[{"type":"DRUG","name":"Esketamine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Duloxetine (Oral Antidepressant)","otherNames":[]},{"type":"DRUG","name":"Escitalopram (Oral Antidepressant)","otherNames":[]},{"type":"DRUG","name":"Sertraline (Oral Antidepressant)","otherNames":[]},{"type":"DRUG","name":"Venlafaxine Extended Release (XR) (New Antidepressant)","otherNames":[]}],"arms":[{"label":"Intranasal Esketamine plus Oral Antidepressant","type":"EXPERIMENTAL"},{"label":"Placebo plus Oral Antidepressant","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.","primaryOutcome":{"measure":"Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis","timeFrame":"Baseline up to Endpoint (Double-blind Induction Phase[Day 28])","effectByArm":[{"arm":"Intranasal Esketamine Plus Oral Antidepressant (AD)","deltaMin":-10,"sd":12.74},{"arm":"Oral AD Plus Intranasal Placebo","deltaMin":-6.3,"sd":8.86}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.059"}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":69,"countries":["United States","Belgium","Brazil","Bulgaria","Finland","France","Lithuania","Poland","South Africa","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["34235612","33128208","32860422"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217051&amp;parentIdentifier=CR107129&amp;attachmentIdentifier=2db249ff-4daf-4ca5-befb-bbf9adbb3653&amp;fileName=ESKETINTRD3005_(CR107129)_Additional_results_data_CH.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":72},"commonTop":["Dizziness","Nausea","Fatigue","Blood Pressure Increased","Headache"]}}